JP2006526650A - Nmda/nr2b拮抗物質としての3−フルオロ−ピペリジン - Google Patents
Nmda/nr2b拮抗物質としての3−フルオロ−ピペリジン Download PDFInfo
- Publication number
- JP2006526650A JP2006526650A JP2006515051A JP2006515051A JP2006526650A JP 2006526650 A JP2006526650 A JP 2006526650A JP 2006515051 A JP2006515051 A JP 2006515051A JP 2006515051 A JP2006515051 A JP 2006515051A JP 2006526650 A JP2006526650 A JP 2006526650A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- aryl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 14
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract description 17
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract description 9
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 2
- YUKQZLBLVRAJSW-UHFFFAOYSA-N 3-fluoropiperidine Chemical compound FC1CCCNC1 YUKQZLBLVRAJSW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 114
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- 208000002193 Pain Diseases 0.000 claims abstract description 24
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 206010015037 epilepsy Diseases 0.000 claims abstract description 6
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 5
- 206010027599 migraine Diseases 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 7
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims description 4
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 3
- 229960004205 carbidopa Drugs 0.000 claims description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 claims description 2
- 239000000775 AMPA receptor antagonist Substances 0.000 claims description 2
- 229940104754 Bradykinin B1 receptor antagonist Drugs 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 229940121869 GABA A receptor agonist Drugs 0.000 claims description 2
- 102000004300 GABA-A Receptors Human genes 0.000 claims description 2
- 108090000839 GABA-A Receptors Proteins 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 229940089973 Sodium channel antagonist Drugs 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 239000003144 bradykinin B1 receptor antagonist Substances 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 2
- 229960003337 entacapone Drugs 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 239000002873 kainic acid receptor antagonist Substances 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 229940072228 neurontin Drugs 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 239000003402 opiate agonist Substances 0.000 claims description 2
- 239000003401 opiate antagonist Substances 0.000 claims description 2
- 229960004851 pergolide Drugs 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 229960003089 pramipexole Drugs 0.000 claims description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 2
- 229960001879 ropinirole Drugs 0.000 claims description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 2
- 229940125794 sodium channel blocker Drugs 0.000 claims description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229960000103 thrombolytic agent Drugs 0.000 claims description 2
- 229960004603 tolcapone Drugs 0.000 claims description 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
- 229940102566 valproate Drugs 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029174 Nerve compression Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 229940127315 Potassium Channel Openers Drugs 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 206010043994 Tonic convulsion Diseases 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 229940005501 dopaminergic agent Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 34
- 239000000243 solution Substances 0.000 description 25
- -1 aryl heterocyclic compounds Chemical class 0.000 description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 16
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- SEGUUECEFSYLBO-UHFFFAOYSA-N [2-[[1-[2-[[8-amino-4,6-dimethyl-7-oxo-1,9-bis[[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]carbamoyl]phenoxazin-3-yl]amino]-2-oxoethoxy]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl] 2-am Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2C1=NC1=C(C(=O)NC3C(NC(C(=O)N4CCCC4C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC3C)C(C)C)=O)C=C(NC(=O)COC(=O)C(C(C)C)NC(=O)COC(=O)C(N)C(C)C)C(C)=C1O2 SEGUUECEFSYLBO-UHFFFAOYSA-N 0.000 description 5
- 108700015902 actinomycin D2 Proteins 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002825 functional assay Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- LMQAMRVSMQXKRF-HZPDHXFCSA-N (4-methylphenyl)methyl (3s,4r)-4-(2-ethoxy-2-oxoethyl)-3-fluoropiperidine-1-carboxylate Chemical compound C1[C@@H](F)[C@@H](CC(=O)OCC)CCN1C(=O)OCC1=CC=C(C)C=C1 LMQAMRVSMQXKRF-HZPDHXFCSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 102000038100 NR2 subfamily Human genes 0.000 description 4
- 108020002076 NR2 subfamily Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LMQAMRVSMQXKRF-JKSUJKDBSA-N (4-methylphenyl)methyl (3S,4S)-4-(2-ethoxy-2-oxoethyl)-3-fluoropiperidine-1-carboxylate Chemical compound C(C)OC(C[C@H]1[C@@H](CN(CC1)C(=O)OCC1=CC=C(C=C1)C)F)=O LMQAMRVSMQXKRF-JKSUJKDBSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000034570 NR1 subfamily Human genes 0.000 description 3
- 108020001305 NR1 subfamily Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- YSIALVLPAPHPRR-UHFFFAOYSA-N [2-[[8-amino-4,6-dimethyl-7-oxo-1,9-bis[[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]carbamoyl]phenoxazin-3-yl]amino]-2-oxoethyl] 2-amino-3-methylbutanoate Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2C1=NC1=C(C(=O)NC3C(NC(C(=O)N4CCCC4C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC3C)C(C)C)=O)C=C(NC(=O)COC(=O)C(N)C(C)C)C(C)=C1O2 YSIALVLPAPHPRR-UHFFFAOYSA-N 0.000 description 3
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 108700015901 actinomycin D1 Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- MMUISACFAXVWKH-HUUCEWRRSA-N (4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(1,3,4-thiadiazol-2-ylamino)methyl]piperidine-1-carboxylate Chemical compound F[C@@H]1CN(CC[C@@H]1CNC=1SC=NN=1)C(=O)OCC1=CC=C(C=C1)C MMUISACFAXVWKH-HUUCEWRRSA-N 0.000 description 2
- ZZRGMJDRDLLVRC-XNTDXEJSSA-N (4-methylphenyl)methyl (4e)-4-(2-ethoxy-2-oxoethylidene)-3-fluoropiperidine-1-carboxylate Chemical compound C1C(F)C(=C/C(=O)OCC)/CCN1C(=O)OCC1=CC=C(C)C=C1 ZZRGMJDRDLLVRC-XNTDXEJSSA-N 0.000 description 2
- ZZRGMJDRDLLVRC-GDNBJRDFSA-N (4-methylphenyl)methyl (4z)-4-(2-ethoxy-2-oxoethylidene)-3-fluoropiperidine-1-carboxylate Chemical compound C1C(F)C(=C/C(=O)OCC)\CCN1C(=O)OCC1=CC=C(C)C=C1 ZZRGMJDRDLLVRC-GDNBJRDFSA-N 0.000 description 2
- YWZLNXFHALMOHI-UHFFFAOYSA-N (4-methylphenyl)methyl 3-fluoro-4-oxopiperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1COC(=O)N1CC(F)C(=O)CC1 YWZLNXFHALMOHI-UHFFFAOYSA-N 0.000 description 2
- OEGDILXHJWLBNR-UHFFFAOYSA-N (4-methylphenyl)methyl 4-oxopiperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1COC(=O)N1CCC(=O)CC1 OEGDILXHJWLBNR-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CMIVUWHQMLZTQD-ZIAGYGMSSA-N 2-[(3s,4r)-3-fluoro-1-[(4-methylphenyl)methoxycarbonyl]piperidin-4-yl]acetic acid Chemical compound C1=CC(C)=CC=C1COC(=O)N1C[C@@H](F)[C@@H](CC(O)=O)CC1 CMIVUWHQMLZTQD-ZIAGYGMSSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- KMTDMTZBNYGUNX-UHFFFAOYSA-N 4-methylbenzyl alcohol Chemical compound CC1=CC=C(CO)C=C1 KMTDMTZBNYGUNX-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010064012 Central pain syndrome Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- COWPAITVMXHKRU-ZIAGYGMSSA-N (4-methylphenyl)methyl (3s,4r)-4-(aminomethyl)-3-fluoropiperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1COC(=O)N1C[C@@H](F)[C@@H](CN)CC1 COWPAITVMXHKRU-ZIAGYGMSSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QACMXJJLQXUOPQ-UHFFFAOYSA-N 1,2-dichloroethane;3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound ClCCCl.CCN=C=NCCCN(C)C QACMXJJLQXUOPQ-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
- PTKKFWSANABKNB-UHFFFAOYSA-N 4-(2-ethoxy-2-oxoethylidene)-3-fluoropiperidine-1-carboxylic acid Chemical compound CCOC(=O)C=C1CCN(C(O)=O)CC1F PTKKFWSANABKNB-UHFFFAOYSA-N 0.000 description 1
- FOWOXWLATUAFNQ-UHFFFAOYSA-N 4-oxopiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(=O)CC1 FOWOXWLATUAFNQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 0 BN(CCC1*NC(CCCCC(C)(C)*)CCCC(C)(C)CCC)CC1F Chemical compound BN(CCC1*NC(CCCCC(C)(C)*)CCCC(C)(C)CCC)CC1F 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RECBFDWSXWAXHY-IAGOWNOFSA-N Cc1ccc(COC(N(CC[C@@H]2CNc3ncccn3)C[C@H]2F)=O)cc1 Chemical compound Cc1ccc(COC(N(CC[C@@H]2CNc3ncccn3)C[C@H]2F)=O)cc1 RECBFDWSXWAXHY-IAGOWNOFSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- MCCSDEXKLKJZIT-IWYXBRTKSA-N NC[C@@H]1[C@@H](CN(CC1)C(=O)OCC1=CC=C(C=C1)C)F.N(N)C(=S)NC[C@@H]1[C@@H](CN(CC1)C(=O)OCC1=CC=C(C=C1)C)F Chemical compound NC[C@@H]1[C@@H](CN(CC1)C(=O)OCC1=CC=C(C=C1)C)F.N(N)C(=S)NC[C@@H]1[C@@H](CN(CC1)C(=O)OCC1=CC=C(C=C1)C)F MCCSDEXKLKJZIT-IWYXBRTKSA-N 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010061339 Perineal pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IOUYHTQXIPFYKF-UHFFFAOYSA-N benzyl 4-(aminomethyl)-3-fluoropiperidine-1-carboxylate Chemical compound C1C(F)C(CN)CCN1C(=O)OCC1=CC=CC=C1 IOUYHTQXIPFYKF-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- ZLFCOBWKGNBHPS-JKSUJKDBSA-N ethyl 2-[(3S,4S)-3-fluoro-1-[(4-methylphenyl)methyl]piperidin-4-yl]acetate Chemical compound CC1=CC=C(CN2C[C@H]([C@@H](CC2)CC(=O)OCC)F)C=C1 ZLFCOBWKGNBHPS-JKSUJKDBSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- YYPWGCZOLGTTER-MZMPZRCHSA-N pergolide Chemical compound C1=CC=C2[C@H]3C[C@@H](CSC)CN(CCC)[C@@H]3CC3=CN=C1[C]32 YYPWGCZOLGTTER-MZMPZRCHSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- AHDDRJBFJBDEPW-DTWKUNHWSA-N trans-2-Phenylcyclopropanecarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-DTWKUNHWSA-N 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
HetArは、1個若しくは2個の窒素環原子を含有する5若しくは6員環芳香族複素環、又はチアゾリル、又はチアジアゾリルであり、
R1及びR2は独立にH、C1−4アルキル、フルオロ、クロロ、ブロモ又はヨードであり、
Aは結合又は−C1−2アルキル−であり、
Bは、アリール(CH2)0−3−O−C(O)−、インダニル(CH2)0−3−O−C(O)−、アリール(CH2)1−3−C(O)−、アリール−シクロプロピル−C(O)−、アリール(CH2)1−3−NH−C(O)−であり、該アリールのいずれも1個から5個の置換基で場合によっては置換されていてもよく、各置換基は独立にC1−4アルキル、フルオロ又はクロロである。
HetArは、1個又は2個の窒素環原子を含有する6員環芳香族複素環である。
HetArは、1個の窒素環原子を含有する6員環芳香族複素環である。
HetArは、2個の窒素環原子を含有する6員環芳香族複素環である。
HetArはチアゾリル又はチアジアゾリルである。
HetArは1,2,4−チアジアゾリルである。
HetArはチアゾリルである。
Aは結合又は−C1−2アルキル−である。
Aは結合である。
Aはメチレンである。
Aは−C2アルキル−である。
Bは、アリール−シクロプロピル−C(O)−又はアリール(CH2)0−3−O−C(O)−であり、該アリールはC1−4アルキルで場合によっては置換されていてもよい。
Bはアリール−シクロプロピル−C(O)−であり、該アリールはC1−4アルキルで場合によっては置換されていてもよいフェニルである。
Bはアリール(CH2)0−3−O−C(O)−であり、該アリールはC1−4アルキルで場合によっては置換されていてもよいフェニルである。
Bはアリール−O−C(O)−であり、該アリールはC1−4アルキルで場合によっては置換されていてもよいフェニルである。
Bはアリール(CH2)−O−C(O)−であり、該アリールはC1−4アルキルで場合によっては置換されていてもよいフェニルである。
Bはアリール(CH2)−O−C(O)−であり、該アリールは4−トリルである。
HetArは、2個の窒素環原子を含有する6員環芳香族複素環であり、
Aはメチレンであり、
Bはアリール(CH2)−O−C(O)−であり、該アリールは4−トリルである。
HetArは、1,2,4−チアジアゾリルであり、
Aはメチレンであり、
Bはアリール(CH2)−O−C(O)−であり、該アリールは4−トリルである。
HetArは、2個の窒素環原子を含有する6員環芳香族複素環であり、
Aはメチレンであり、
Bはアリール−シクロプロピル−C(O)−であり、該アリールはC1−4アルキルで場合によっては置換されていてもよいフェニルである。
NR2B拮抗物質のIC50を決定する細胞ベースの機能アッセイ
NR1a/NR2B受容体によって媒介されるCa2+流入によって測定される選択化合物のNR1a/NR2B NMDA受容体阻害能力は、以下のカルシウム流入アッセイ手順によって評価された。
放射性リガンド結合アッセイは、96ウェルマイクロタイタープレートにおいて150mM NaClを含有する20mM Hepes緩衝剤(pH7.4)中1.0mLの最終アッセイ体積で室温で実施された。NR2B拮抗物質溶液は、DMSO中で調製され、DMSOで連続希釈して濃度が3倍異なる10種類の溶液が各々20μL得られた。非特異的結合(NSB)はAMD−1(10μM最終濃度)を用いて評価され、全結合量(TB)は、DMSO(2%最終濃度)を添加して測定された。NR1a/NR2B受容体(40pM最終濃度)を発現する膜及びトリチウム化AMD−2(1nM最終濃度)がマイクロタイタープレートの全ウェルに添加された。室温で3時間インキュベーションした後に、試料を(0.05%PEI、ポリエチレンイミンSigma P−3143にあらかじめ浸漬された)Packard GF/Bフィルターを通してろ過し、1回の洗浄につき冷20mM Hepes緩衝剤1mLで10回洗浄する。ろ板を真空乾燥させた後に、Packard Microscint−20 40μLを添加し、結合放射能をPackard TopCountで測定した。見掛け解離定数(KI)、最大阻害率(%Imax)、最小阻害率(%Imin)及び傾き(hill slope)(nH)を、下記式#2に結合放射能(結合CPM)を非線形最小二乗フィッティングさせて求めた。
CDI 1,1’−カルボニルジイミダゾール
TEA トリエチルアミン
TBSCl 塩化t−ブチルジメチルシリル
DMF ジメチルホルムアミド
(+)−BINAP (+)−2,2’−Bis(ジフェニルホスフィノ)−1,1’−ビナフチル
NaOtBu ナトリウムt−ブトキシド
DIPEA ジイソプロピルエチルアミン
EtOAc 酢酸エチル
TBSOTf t−ブチルジメチルシリルトリフレート
TBS t−ブチルジメチルシリル
THF テトラヒドロフラン
DMAP 4−ジメチルアミノピリジン
RT 室温
h 時間
min 分
DCM ジクロロメタン
MeCN アセトニトリル
iPrOH 2−プロパノール
n−BuOH 1−ブタノール
EDC 1−(3−ジメチルアミノプロピル)−3−エチルカルボジイミド塩酸塩
HOAt 1−ヒドロキシ−7−アザベンゾトリアゾール
(実施例1)
4−メチルベンジル4−オキソピペリジン−1−カルボキシラートの調製
HRMS(ES) m/z 248.1281 [(M+H)+;C14H18NO3の計算値:248.1287];
分析値 C14H17NO3:C、68.03;H、7.05;N、5.59。実測値:C、68.00;H、6.93;N、5.66。
(±)−4−メチルベンジル3−フルオロ−4−オキソピペリジン−1−カルボキシラートの調製
分析値 C14H18FNO4・1.2H2O:C、58.61;H、6.46;N、4.88。実測値:C、58.28;H、6.06;N、4.72。
及び
の調製
室温の(±)−4−メチルベンジル3−フルオロ−4−オキソピペリジン−1−カルボキシラート(40g、150mmol)のトルエン(200mL)溶液に(カルボエトキシメチレン)トリフェニルホスホラン(63.0g、181mmol)を添加し、反応混合物を1時間撹拌した。反応混合物を濃縮し、シリカゲルクロマトグラフィー(勾配溶出:10%から20%EtOAcのへキサン溶液)によって精製して、3:1 E:Z混合物としてオレフィン(±)−4−メチルベンジル(E)−4−(2−エトキシ−2−オキソエチリデン)−3−フルオロピペリジン−1−カルボキシラート及び(±)−4−メチルベンジル(Z)−4−(2−エトキシ−2−オキソエチリデン)−3−フルオロピペリジン−1−カルボキシラート(41.0g、78%収率、3段階)を得た。この混合物を次の段階に直接利用した。この混合物の少量の試料をキャラクタリゼーションのためにシリカゲルクロマトグラフィーによって分離させた。
1H NMR(400MHz、CDCl3) δ 7.26(d、2 H)、7.17(d、2 H)、5.98(s、1 H)、5.11(s、2 H)、4.85(m、1 H)、4.18(q、2 H)、4.08(br d、1 H)、3.70(m、1 H)、3.55(m、1 H) 3.41(m、1 H)、3.33、(m、1 H)、2.63(br d、1 H)、2.35(s、3 H)、1.29(t、3 H) ppm;
HRMS(ES) m/z 358.1420 [(M+Na)+;C18H22FNO4Naの計算値:358.1425];
分析値 C18H22FNO4:C、64.21;H、6.58;N、4.27。実測値:C、64.46;H、6.61;N、4.18。
1H NMR(400MHz、CDCl3) δ 7.24(d、2 H)、7.15(d、2 H)、6.41(m、1 H)、5.82(s、1 H)、5.11(d、2 H)、4.61(m、1 H)、4.38(br d、1 H)、4.16(q、2 H)、3.05−2.95(m、1 H)、2.9−2.75(m、2 H)、2.33(s、3 H)、2.13(m、1 H)、1.27(t、3 H) ppm;
HRMS(ES) m/z 358.1422 [(M+Na)+;C18H22FNO4Naの計算値:358.1425]。
及び
の調製
段階3から得られたオレフィン混合物(10.0g、29.8mmol)のトルエン(160mL)とCH2Cl2(120mL)の溶液にジフェニルシラン(5.53mL、29.8mmol)及び(R)−BINAP(1.86g、2.98mmol)を添加した。次いで、ナトリウムt−ブトキシド(0.29g、2.98mmol)及びCuCl(0.30g、2.98mmol)を添加し、反応混合物を光から遮断し15時間撹拌した。追加のジフェニルシラン(2.76mL)、NaOtBu(0.29g)及びCuCl(0.30g)を添加し、反応混合物を室温で24時間撹拌した。次いで、混合物をセライトを通してろ過し、濃縮した。シリカゲル(段階的勾配溶出:5%、10%、15%、25%、30%EtOAcのへキサン溶液)によって精製して、回収出発材料(3.5g、35%収率)、(±)−シス4−メチルベンジル4−(2−エトキシ−2−オキソエチル)−3−フルオロピペリジン−1−カルボキシラート(5.0g、50%収率)及び(±)−トランス4−メチルベンジル4−(2−エトキシ−2−オキソエチル)−3−フルオロピペリジン−1−カルボキシラート(1.2g、12%収率)を得た。
1H NMR(400MHz、CDCl3) δ 7.25(d、2 H)、7.15(d、2 H)、5.10(s、2 H)、4.80−4.20(m、3 H)、4.15(q、2 H)、3.10−2.73(m、2 H)、2.52(dd、1 H)、2.35(s、3 H)、2.30(dd、1 H)、2.10(m、1 H)、1.72−1.48(m、2 H)、1.29(t、3 H) ppm;
HRMS(ES) m/z 338.1689 [(M+H)+;C18H25FNO4の計算値:338.1762]。
1H NMR(400MHz、CDCl3) δ 7.24(d、2 H)、7.15(d、2 H)、5.08(s、2 H)、4.50−3.95(m、3 H)、4.15(q、2 H)、2.81(br t、2 H)、2.70(br d、1 H)、2.35(s、3 H)、2.17(m、2 H)、1.89(br d、1 H)、1.25(m、1 H)、1.22(t、3 H) ppm;
HRMS(ES) m/z 338.1699 [(M+H)+;の計算値C18H25FNO4:338.1762]。
(±)−((シス)−3−フルオロ−1−{[(4−メチルベンジル)オキシ]カルボニル}ピペリジン−4−イル)酢酸の調製
HRMS(ES) m/z 310.1457 [(M+H)+;C16H21FNO4の計算値:310.1449]。
分析値 C16H20FNO4・0.15H2O:C、62.13;H、6.52;N、4.53。実測値:C、61.55;H、6.37;N、4.41。
(±)−シス−4−メチルベンジル4−(アミノメチル)−3−フルオロピペリジン−1−カルボキシラートの調製
HRMS(ES) m/z 281.1658 [(M+H)+;C15H22FN2O2の計算値:281.1660]。
及び
の調製
2個の封管に粗製(±)−シス−4−メチルベンジル4−(アミノメチル)−3−フルオロピペリジン−1−カルボキシラート(段階6、3.7g、13.2mmol)と2−クロロピリミジン(1.51g、13.2mmol)の混合物のn−ブタノール/ジイソプロピル−エチルアミン(1:1、13mL)溶液を各々充填した。封管を密封し、混合物を140℃に加熱し、2時間撹拌した。室温に冷却後、反応混合物を混合し、EtOAc及び飽和NaHCO3で希釈した。層を分離させ、有機層をH2O及び塩水で洗浄し、Na2SO4を用いて脱水し、ろ過し、濃縮した。シリカゲルクロマトグラフィー(勾配溶出:1:1 へキサン:EtOAcからEtOAc)によって精製して、白色固体のラセミシス−4−メチルベンジル3−フルオロ−4−[(ピリミジン−2−イルアミノ)メチル]ピペリジン−1−カルボキシラート(6.9g、65%収率、3段階)を得た。
[α]D−36.4°(c 0.17、MeOH);
融点 149−150℃;
1H NMR(400MHz、CD3OD) δ 8.58(br s、2 H)、7.21(d、2 H)、7.17(d、2 H)、6.99(t、1 H)、5.06(s、2 H)、4.79(m、1 H)、4.42(t、1 H)、4.21(d、1 H)、3.60(dd、1 H)、3.50(dd、1 H)、3.15−2.80(m、2 H)、2.30(s、3 H)、2.10(m、1 H)、1.61(m、2 H) ppm;
HRMS(ES) m/z 359.1879 [(M+H)+;C19H24FN4O2の計算値:359.1878];
分析値 C19H23FN4O2・HCl・0.2H2O:C、57.27;H、6.17;N、14.06。実測値:C、57.22;H、6.37;N、14.16。
[α]D+34.9°(c 0.18、MeOH);
融点149−150℃;
1H NMR(400MHz、CD3OD) δ 8.58(br s、2 H)、7.21(d、2 H)、7.17(d、2 H)、6.99(t、1 H)、5.06(s、2 H)、4.79(m、1 H)、4.42(t、1 H)、4.21(d、1 H)、3.60(dd、1 H)、3.50(dd、1 H)、3.15−2.80(m、2 H)、2.30(s、3 H)、2.10(m、1 H)、1.61(m、2 H) ppm;
HRMS(ES) m/z 359.1870 [(M+H)+;C19H24FN4O2の計算値:359.1878]。
分析値 C19H23FN4O2・HCl・0.5H2O:C、56.50;H、6.24;N、13.87。実測値:C、56.68;H、6.27;N、13.80。
標記化合物は、実施例1及び2の段階5、6及び7に記載の手順を利用して、(±)−トランス4−メチルベンジル4−(2−エトキシ−2−オキソエチル)−3−フルオロピペリジン−1−カルボキシラート(実施例1及び2、段階4)から調製された。
[α]D−11.5°(c 0.22、MeOH);
融点113−114℃;
1H NMR(400MHz、CD3OD) δ 8.80−8.39(m、2 H)、7.24(d、2 H)、7.15(d、2 H)、7.00(t、1 H)、5.08(s、2 H)、4.49−4.21(m、2 H)、4.00(d、1 H)、3.81(dd、1H)、3.58(dd、1 H)、2.95(m、1 H)、2.31(s、3 H)、2.12(m、1 H)、1.90(m、1 H)、1.34(m、1 H) ppm;
HRMS(ES) m/z 359.1867 [(M+H)+;C19H24FN4O2の計算値:359.1878]。
分析値 C19H23FN4O2・HCl・H2O:C、55.27;H、6.35;N、13.57。実測値:C、55.08;H、6.11;N、13.36。
[α]D+16.3°(c 0.17、MeOH);
融点113−114℃
1H NMR(400MHz、CD3OD) δ 8.80−8.39(m、2 H)、7.24(d、2 H)、7.15(d、2 H)、7.00(t、1 H)、5.08(s、2 H)、4.49−4.21(m、2 H)、4.00(d、1 H)、3.81(dd、1H)、3.58(dd、1 H)、2.95(m、1 H)、2.31(s、3 H)、2.12(m、1 H)、1.90(m、1 H)、1.34(m、1 H) ppm;
HRMS(ES) m/z 359.1873 [(M+H)+;C19H24FN4O2の計算値:359.1878];
分析値 C19H23FN4O2・HCl・H2O:C、55.27;H、6.35;N、13.57。実測値:C、55.18;H、6.11;N、13.38。
の調製
融点127−128℃;
1H NMR(400MHz、CD3OD) δ 8.59(br s、2 H)、7.25(m、2 H)、7.17(m、3 H)、7.01(t、1 H)、4.85(m、2 H)、4.65−4.30(m、2 H)、3.55(m、2 H)、3.30(m、1 H)、2.80 m、1 H)、2.39(m、1 H)、2.30−2.10(m、2 H)、1.75(m、1 H)、1.55(m、2 H)、1.33(m、1 H) ppm;
HRMS(ES) m/z 355.1925 [(M+H)+;C20H24FN4Oの計算値:355.1929];
分析値 C20H23FN4O・HCl・H2O:C、58.75;H、6.41;N、13.70。実測値:C、58.57;H、6.44;N、13.54。
段階1
の調製
(±)−シス−4−メチルベンジル4−(アミノメチル)−3−フルオロピペリジン−1−カルボキシラート(実施例1、段階6)(200mg、0.71mmol)のDMF(2mL)溶液をチオカルボニルジイミダゾール(127mg、0.71mmol)のDMF(4mL)撹拌冷却(0℃)溶液に滴下した。反応混合物を30分間撹拌し、冷却浴を除去し、反応混合物を室温で1時間撹拌した。次いで、ヒドラジン(0.066mL、2.14mmol)を添加し、反応混合物をさらに30分間撹拌した。反応混合物を水中に注ぎ、酢酸エチルで抽出した。有機層を炭酸水素ナトリウム飽和溶液、水及び塩水で洗浄し、硫酸ナトリウムを用いて脱水し、溶媒を減圧下で蒸発させて固体の粗製生成物を得た。この粗製固体をメタノール(10mL)を用いてすり潰し、ろ過して標記化合物180mgを得た。
段階2
(−)−シス−4−メチルベンジル3−フルオロ−4−[(1,3,4−チアジアゾル−2−イルアミノ)メチル]ピペリジン−1−カルボキシラート
(±)−シス4−メチルベンジル4−{[(ヒドラジノカルボノチオイル)アミノ]メチル}−3−フルオロピペリジン−1−カルボキシラート(180mg、0.51mmol)のエタノール(10mL)懸濁液をオルトギ酸トリエチル(151mg、1.02mmol)及び濃HCl(0.01mL)で処理し、窒素下、室温で18時間撹拌した。すべての固体が溶解した後に、反応混合物を1.5時間加熱還流し、室温に冷却し、揮発性物質を蒸発させた。残渣を酢酸エチルと炭酸水素ナトリウム希薄溶液に分配させ、有機層を塩水で洗浄し、硫酸ナトリウムを用いて脱水し、溶媒を蒸発させた。粗製生成物をシリカゲル(50%酢酸エチル:へキサンから20%メタノール:酢酸エチル)上で勾配溶出によって精製して白色固体の標記化合物を得た。(−)−鏡像異性体を分離し、実施例1及び2段階7に記載のとおりその塩酸塩を形成させた。
融点115−117℃;
1H NMR(400MHz、CDCl3) δ 8.37(s、1 H)、7.25(d、2 H)、7.16(d、2 H)、6.57(br s、1 H)、5.10(d、2 H)、4.79(dd、1 H)、4.56(m、1 H)、4.29(m、1 H)、3.44(d、2 1−1)、3.10−2.77(m、2 H)、2.35(s、3 H)、2.2(m、1 H)、1.63(m、2 H);
HRMS(ES) m/z 365.1437 [(M+H)+;C17H22FN4O2Sの計算値:365.1442]。
分析値 C17H21FN4O2S:C、56.03;H、5.81;N、15.37。実測値:C、55.82;H、5.74;N、15.11。
標記化合物は、実施例1及び2、段階5及び6に記載の手順を利用し、続いて、実施例6に記載のチアジアゾールの形成を利用し、(±)−トランス4−メチルベンジル4−(2−エトキシ−2−オキソエチル)−3−フルオロピペリジン−1−カルボキシラート(実施例1及び2、段階4)から調製された。(+)−鏡像異性体を、実施例1及び2段階7に記載のキラルHPLCによって分離した。
融点93−95℃;
1H NMR(400MHz、CDCl3) δ 8.36(s、1 H)、7.28(d、2 H)、7.19(d、2 H)、6.56(br s、1 H)、5.04(s、2 H)、4.45(m、2 H)、4.17(m、1 H)、3.56(m、2 H)、2.80(m、2 H)、2.35(s、3 H)、2.10(m、1 H)、1.96(m、1 H)、1.39(m、1 H) ppm;
HRMS(ES) m/z 365.1432 [(M+H)+;C17H22FN4O2Sの計算値:365.1442];
分析値 C17H21FN4O2S・0.25H2O:C、55.34;H、5.87;N、15.19。実測値:C、55.50;H、5.61;N、14.81。
Claims (46)
- 式(I)の化合物、又は薬剤として許容されるその塩。
HetArは、1個若しくは2個の窒素環原子を含有する5若しくは6員環芳香族複素環、チアゾリル又はチアジアゾリルであり、
HetArは、1個又は2個の置換基で場合によっては置換されていてもよく、各置換基は独立にC1−4アルキル、フルオロ、クロロ、ブロモ又はヨードであり、
Aは結合又は−C1−2アルキル−であり、
Bは、アリール(CH2)0−3−O−C(O)−、インダニル(CH2)0−3−O−C(O)−、アリール(CH2)1−3−C(O)−、アリール−シクロプロピル−C(O)−、アリール(CH2)1−3−NH−C(O)−であって、該アリールのいずれもが1個から5個の置換基で場合によっては置換されていてもよく、各置換基は独立にC1−4アルキル、フルオロ又はクロロである。) - HetArが、1個の窒素環原子を含有する6員環芳香族複素環である、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- HetArが、2個の窒素環原子を含有する6員環芳香族複素環である、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- HetArがチアゾリルである、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- HetArがチアジアゾリルである、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- HetArが1,2,4−チアジアゾリルである、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- Aが結合である、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- Aがメチレンである、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- Aが−C2アルキル−である、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- Bがアリール−シクロプロピル−C(O)−であって、前記アリールが請求項1に記載されたように場合によっては置換されていてもよい、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- 前記アリールが、請求項1に記載されたように場合によっては置換されていてもよいフェニルである、請求項10に記載の化合物、又は薬剤として許容されるその塩。
- Bがアリール(CH2)0−3−O−C(O)−であって、前記アリールが請求項1に記載されたように場合によっては置換されていてもよい、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- Bがアリール(CH2)−O−C(O)−であって、前記アリールが請求項1に記載されたように場合によっては置換されていてもよい、請求項1に記載の化合物、又は薬剤として許容されるその塩。
- 前記アリールがC1−4アルキルで場合によっては置換されていてもよい、請求項13に記載の化合物、又は薬剤として許容されるその塩。
- 前記アリールが4−トリルである、請求項14に記載の化合物、又は薬剤として許容されるその塩。
- HetArが、2個の窒素環原子を含有する6員環芳香族複素環であり、
Aがメチレンであり、
Bがアリール(CH2)−O−C(O)−であって、前記アリールが請求項1に記載されたように場合によっては置換されていてもよい、請求項1に記載の化合物、又は薬剤として許容されるその塩。 - 前記アリールがC1−4アルキルで場合によっては置換されていてもよい、請求項16に記載の化合物、又は薬剤として許容されるその塩。
- 前記アリールが4−トリルである、請求項17に記載の化合物、又は薬剤として許容されるその塩。
- HetArが、2個の窒素環原子を含有する6員環芳香族複素環であり、
Aがメチレンであり、
Bが4−トリル(CH2)−O−C(O)−である、請求項1に記載の化合物、又は薬剤として許容されるその塩。 - HetArがチアジアゾリルであり、
Aがメチレンであり、
Bがアリール(CH2)−O−C(O)−であって、前記アリールが請求項1に記載されたように場合によっては置換されていてもよい、請求項1に記載の化合物、又は薬剤として許容されるその塩。 - HetArが1,2,4−チアジアゾリルであり、
Aがメチレンであり、
Bが4−トリル(CH2)−O−C(O)−である、請求項1に記載の化合物、又は薬剤として許容されるその塩。 - HetArが、2個の窒素環原子を含有する6員環芳香族複素環であり、
Aがメチレンであり、
Bがアリール−シクロプロピル−C(O)−である、請求項1に記載の化合物、又は薬剤として許容されるその塩。 - HetArが、2個の窒素環原子を含有する6員環芳香族複素環であり、
Bがフェニル−シクロプロピル−C(O)−である、請求項1に記載の化合物、又は薬剤として許容されるその塩。 - 不活性担体及び請求項1に記載の化合物の治療有効量を含む薬剤組成物。
- (i)非ステロイド性抗炎症剤、(ii)COX−2阻害剤、(iii)ブラジキニンB1受容体拮抗物質、(iv)ナトリウムチャネル遮断薬及び拮抗物質、(v)一酸化窒素シンターゼ(NOS)阻害剤、(vi)グリシンサイト拮抗物質、(vii)カリウムチャネル開口薬、(viii)AMPA/カイニン酸受容体拮抗物質、(ix)カルシウムチャネル拮抗物質、(x)GABA−A受容体モジュレーター(例えば、GABA−A受容体作用物質)、(xi)マトリックスメタロプロテアーゼ(MMP)阻害剤、(xii)血栓溶解剤、(xiii)モルヒネなどのオピオイド、(xiv)好中球抑制因子(NIF)、(xv)Lドーパ、(xvi)カルビドパ、(xvii)レボドパ/カルビドパ、(xviii)ブロモクリプチン、ペルゴリド、プラミペキソール、ロピニロールなどのドーパミン作用物質、(xix)抗コリン薬、(xx)アマンタジン、(xxi)カルビドパ、(xxii)エンタカポン及びトルカポンなどのカテコールO−メチルトランスフェラーゼ(「COMT」)阻害剤、(xxiii)モノアミン酸化酵素B(「MAO−B」)阻害剤、(xiv)オピエート作用物質又は拮抗物質、(xv)5HT受容体作用物質又は拮抗物質、(xvi)NMDA受容体作用物質又は拮抗物質、(xvii)NK1拮抗物質、(xviii)選択的セロトニン再取り込み阻害薬(「SSRI」)及び/又は選択的セロトニン及びノルエピネフリン再取り込み阻害薬(「SSNRI」)、(xxix)三環系抗うつ薬、(xxx)ノルエピネフリンモジュレーター、(xxxi)リチウム、(xxxii)バルプロエート並びに(xxxiii)ニューロンチン(ガバペンチン)からなる群から選択される第2の治療薬をさらに含む、請求項32に記載の薬剤組成物。
- とう痛、片頭痛、統合失調症、うつ病、不安、群発性頭痛、アルツハイマー病、発作又はてんかんの治療に有用な、請求項32に記載の薬剤組成物。
- とう痛、片頭痛、統合失調症、うつ病、不安、群発性頭痛、アルツハイマー病、発作又はてんかんの治療に有用な、請求項33に記載の薬剤組成物。
- パーキンソン病の治療に有用な、請求項32に記載の薬剤組成物。
- パーキンソン病の治療に有用な、請求項33に記載の薬剤組成物。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者におけるとう痛を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者における片頭痛、群発性頭痛、うつ病、不安、統合失調症、アルツハイマー病又は発作を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者におけるパーキンソン病を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者における慢性、内臓、炎症性及び神経因性とう痛症候群を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者における外傷性神経損傷、神経圧迫又は神経絞やく、帯状ほう疹後神経痛、三叉神経痛、糖尿病性神経障害、癌及び化学療法に起因するとう痛、又は付随するとう痛を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者における慢性腰痛を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者における幻肢痛を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者におけるHIV及びHIV治療による神経障害、慢性骨盤痛、神経腫痛、複合性局所とう痛症候群、慢性関節炎痛及び関係する神経痛を治療又は予防する方法。
- 請求項1に記載の化合物、又は薬剤として許容されるその塩の治療有効量若しくは予防有効量をそれを必要とする患者に投与することを含む、前記患者におけるてんかん並びに部分的及び全身性強直発作を治療又は予防する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47593803P | 2003-06-04 | 2003-06-04 | |
PCT/US2004/017175 WO2004108705A1 (en) | 2003-06-04 | 2004-05-28 | 3-fluoro-piperidines as nmda/nr2b antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006526650A true JP2006526650A (ja) | 2006-11-24 |
JP3927228B2 JP3927228B2 (ja) | 2007-06-06 |
Family
ID=33511734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006515051A Expired - Lifetime JP3927228B2 (ja) | 2003-06-04 | 2004-05-28 | Nmda/nr2b拮抗物質としての3−フルオロ−ピペリジン |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1648882B1 (ja) |
JP (1) | JP3927228B2 (ja) |
KR (1) | KR20060017839A (ja) |
CN (1) | CN1798744A (ja) |
AR (1) | AR044579A1 (ja) |
AT (1) | ATE403651T1 (ja) |
AU (1) | AU2004245522B2 (ja) |
BR (1) | BRPI0410837A (ja) |
CA (1) | CA2527093C (ja) |
CL (1) | CL2004001365A1 (ja) |
CO (1) | CO5700762A2 (ja) |
DE (1) | DE602004015610D1 (ja) |
DK (1) | DK1648882T3 (ja) |
EC (1) | ECSP056192A (ja) |
ES (1) | ES2309540T3 (ja) |
HR (1) | HRP20080490T3 (ja) |
IS (1) | IS8117A (ja) |
MA (1) | MA27781A1 (ja) |
MX (1) | MXPA05013151A (ja) |
MY (1) | MY138547A (ja) |
NO (1) | NO20060020L (ja) |
PE (1) | PE20050245A1 (ja) |
PL (1) | PL1648882T3 (ja) |
PT (1) | PT1648882E (ja) |
RU (1) | RU2339630C2 (ja) |
SI (1) | SI1648882T1 (ja) |
TW (1) | TW200510378A (ja) |
UA (1) | UA81319C2 (ja) |
WO (1) | WO2004108705A1 (ja) |
ZA (1) | ZA200509000B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506514A (ja) * | 2014-12-23 | 2018-03-08 | セレコー,インコーポレイテッド | 化合物、組成物および方法 |
JP2018522831A (ja) * | 2015-06-01 | 2018-08-16 | リューゲン ホールディングス (ケイマン) リミテッド | Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物 |
US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007247851A1 (en) * | 2006-05-03 | 2007-11-15 | Relevare Aust. Pty Ltd | Methods and composition for treatment of inflammatory pain |
EP2148879B1 (en) * | 2007-04-23 | 2012-11-28 | Janssen Pharmaceutica, N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
EP2175886A1 (en) * | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
SG183111A1 (en) | 2010-02-16 | 2012-09-27 | Pfizer | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
WO2013156614A1 (en) | 2012-04-20 | 2013-10-24 | Ucb Pharma S.A. | Methods for treating parkinson's disease |
CN103936663B (zh) * | 2013-01-23 | 2016-12-28 | 艾琪康医药科技(上海)有限公司 | 一种1-r1-3,3-二氟(或3-氟)-4-r2-4-氨甲基哌啶及其衍生物的制备方法 |
US9221796B2 (en) | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
US9187506B2 (en) | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
TW201609741A (zh) | 2014-06-04 | 2016-03-16 | 盧郡控股(開曼)有限公司 | 作為nr2b nmda受體拮抗劑之二氟乙基吡啶衍生物 |
CA2957898C (en) | 2014-09-15 | 2023-02-21 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
US20180271869A1 (en) * | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
US10344020B2 (en) | 2015-10-14 | 2019-07-09 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
JP6843853B2 (ja) | 2015-10-14 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 選択的nr2bアンタゴニスト |
US10227349B2 (en) | 2016-08-31 | 2019-03-12 | Eisai R&D Management Co., Ltd. | Pyrazolo[1,5-a]pyrimidine compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA005974B1 (ru) * | 2001-02-23 | 2005-08-25 | Мерк Энд Ко., Инк. | N-замещенные неарильные гетероциклические антагонисты nmda/nr2b |
-
2004
- 2004-05-28 JP JP2006515051A patent/JP3927228B2/ja not_active Expired - Lifetime
- 2004-05-28 KR KR1020057023218A patent/KR20060017839A/ko not_active Application Discontinuation
- 2004-05-28 AU AU2004245522A patent/AU2004245522B2/en active Active
- 2004-05-28 ES ES04753896T patent/ES2309540T3/es not_active Expired - Lifetime
- 2004-05-28 EP EP04753896A patent/EP1648882B1/en not_active Expired - Lifetime
- 2004-05-28 RU RU2005137704/04A patent/RU2339630C2/ru not_active IP Right Cessation
- 2004-05-28 CN CNA2004800153228A patent/CN1798744A/zh active Pending
- 2004-05-28 AT AT04753896T patent/ATE403651T1/de not_active IP Right Cessation
- 2004-05-28 PL PL04753896T patent/PL1648882T3/pl unknown
- 2004-05-28 SI SI200430845T patent/SI1648882T1/sl unknown
- 2004-05-28 WO PCT/US2004/017175 patent/WO2004108705A1/en active Application Filing
- 2004-05-28 BR BRPI0410837-0A patent/BRPI0410837A/pt not_active IP Right Cessation
- 2004-05-28 DK DK04753896T patent/DK1648882T3/da active
- 2004-05-28 UA UAA200511411A patent/UA81319C2/uk unknown
- 2004-05-28 PT PT04753896T patent/PT1648882E/pt unknown
- 2004-05-28 DE DE602004015610T patent/DE602004015610D1/de not_active Expired - Lifetime
- 2004-05-28 MX MXPA05013151A patent/MXPA05013151A/es active IP Right Grant
- 2004-05-28 CA CA002527093A patent/CA2527093C/en not_active Expired - Lifetime
- 2004-05-31 AR ARP040101878A patent/AR044579A1/es unknown
- 2004-05-31 MY MYPI20042091A patent/MY138547A/en unknown
- 2004-06-01 PE PE2004000552A patent/PE20050245A1/es not_active Application Discontinuation
- 2004-06-03 CL CL200401365A patent/CL2004001365A1/es unknown
- 2004-06-03 TW TW093115972A patent/TW200510378A/zh unknown
-
2005
- 2005-11-07 ZA ZA200509000A patent/ZA200509000B/en unknown
- 2005-11-07 IS IS8117A patent/IS8117A/is unknown
- 2005-11-28 MA MA28626A patent/MA27781A1/fr unknown
- 2005-11-29 EC EC2005006192A patent/ECSP056192A/es unknown
- 2005-11-30 CO CO05121658A patent/CO5700762A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060020A patent/NO20060020L/no not_active Application Discontinuation
-
2008
- 2008-10-01 HR HR20080490T patent/HRP20080490T3/xx unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506514A (ja) * | 2014-12-23 | 2018-03-08 | セレコー,インコーポレイテッド | 化合物、組成物および方法 |
US10710976B2 (en) | 2014-12-23 | 2020-07-14 | Cerecor Inc. | Compounds, compositions and methods |
JP2018522831A (ja) * | 2015-06-01 | 2018-08-16 | リューゲン ホールディングス (ケイマン) リミテッド | Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物 |
US11136328B2 (en) | 2015-06-01 | 2021-10-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
US11752155B2 (en) | 2016-11-22 | 2023-09-12 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3927228B2 (ja) | Nmda/nr2b拮抗物質としての3−フルオロ−ピペリジン | |
CA3050853A1 (en) | Heterocyclic spiro compounds as magl inhibitors | |
TW202003505A (zh) | 甲基修飾酵素之調節劑、其組成物及用途 | |
EP3544972B1 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
KR20170018913A (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
EP3466962A1 (en) | Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof | |
JP2017533253A (ja) | アルツハイマー病を治療するための、bace1阻害剤としての2−アミノ−3,5−ジフルオロ−3,6−ジメチル−6−フェニル−3,4,5,6−テトラヒドロピリジン | |
TR201816427T4 (tr) | Bace1 inhibitörleri olarak 2-amino-6-(diflorometil)-5,5-difloro-6-fenil-3,4,5,6-tetrahidropiridinler. | |
CA3103166A1 (en) | Compounds | |
JP2017533251A (ja) | Bace1阻害剤としての2−アミノ−5,5−ジフルオロ−6−(フルオロメチル)−6−フェニル−3,4,5,6−テトラヒドロピリジン | |
JP2003012653A (ja) | キナゾリン誘導体 | |
TW201920196A (zh) | 作為vanin抑制劑之雜芳族化合物 | |
TWI444376B (zh) | 脯胺醯胺吡啶化合物、其藥學組成物及醫藥用途 | |
JP2024501641A (ja) | 置換大環状化合物及び関連する治療方法 | |
KR20130122531A (ko) | Mglur5 양성 알로스테릭 조절물로서 치환된 6메틸니코틴아미드 | |
JP6816105B2 (ja) | ブロモドメイン阻害剤としてのベンゾジアゼピン | |
US20120252800A1 (en) | Bicyclic thiazoles as allosteric modulators of mglur5 receptors | |
KR20180101568A (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
US7592360B2 (en) | 3-fluoro-piperidines as NMDA/NR2B antagonists | |
CA3049192A1 (en) | Tetrahydroquinoline derivatives as p2x7 receptor antagonists | |
US20060160853A1 (en) | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | |
JP2009517483A (ja) | 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体 | |
JP6449277B2 (ja) | イミダゾールカルボキサミドおよびfaah阻害剤としてのそれらの使用 | |
TW202033529A (zh) | 作為magl抑制劑之雜環螺環化合物 | |
JPH06116273A (ja) | 三環系化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070301 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3927228 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 4 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120309 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120309 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130309 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130309 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140309 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140309 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |